FARAPULSE™ Pulsed Field Ablation System
← catalyst calendarNCT06762717 · readout in 499 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
500estimated
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-23 | actual | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Paroxysmal AF
Intervention
- Device: FARAPULSE™ Pulsed Field Ablation system
Primary outcomes
what the primary-completion date above is the date OFFailure-free rate
measured 12 Months
Device-or procedure-related SAEs:
measured 7 days and 12 months
Procedure- and device related adverse events
measured 12 Months and 2 years and 3 years
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed